Thornburg Investment Management Inc. Lowers Stock Position in Repligen Co. (NASDAQ:RGEN)

Thornburg Investment Management Inc. lessened its stake in shares of Repligen Co. (NASDAQ:RGEN) by 1.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,366 shares of the biotechnology company’s stock after selling 491 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Repligen were worth $5,091,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. UMB Bank n.a. boosted its stake in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares during the period. Oppenheimer & Co. Inc. purchased a new position in Repligen during the fourth quarter worth about $216,000. Van ECK Associates Corp boosted its stake in shares of Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after purchasing an additional 3,066 shares during the period. Stephens Investment Management Group LLC boosted its stake in shares of Repligen by 7.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after purchasing an additional 37,057 shares during the period. Finally, Artemis Investment Management LLP boosted its stake in shares of Repligen by 18.4% in the fourth quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company’s stock valued at $22,143,000 after purchasing an additional 23,905 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 2.6%

Shares of NASDAQ:RGEN opened at $126.50 on Monday. The firm’s 50 day moving average price is $132.74 and its 200 day moving average price is $145.20. The stock has a market cap of $7.11 billion, a price-to-earnings ratio of -248.04, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million for the quarter, compared to analysts’ expectations of $163.65 million. During the same quarter last year, the company earned $0.28 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. As a group, equities research analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on RGEN shares. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective for the company. Canaccord Genuity Group lowered their price objective on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. Wolfe Research raised shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective for the company in a research note on Tuesday, April 29th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Thursday, May 8th. Finally, TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $173.25.

Insiders Place Their Bets

In related news, Director Margaret Pax acquired 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.